Axol Bioscience
Axol Bioscience are human cell culture specialists, providing primary cells and iPSC derived cells with a wide range of functionally and physiologically, disease relevant backgrounds, together with optimised media and growth supplements.
Axol Bioscience has raised €6.2M across 2 funding rounds from 7 investors, most recently a round in Jan 2026. Based in Cambridge, UK; active in Healthtech. Data as of 28 Oct 2026.
Cambridge, UKwww.axolbio.com ↗
Total raised
€6.2M
€6,247,811
Funding rounds
2
Investors
7
distinct backers
Active since
2022-04
latest 2026-01
Funding by year
EUR raised per year · 2026 YTDAxol Bioscience — funding by year — interactive chart.
Data table
| Axol Bioscience — funding by year | |
|---|---|
| 2022 | €3.8M |
| 2026 | €2.4M |
Signals
High confidenceRaise-next likelihood29
base rate 30% for Other
- ▲ In typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood14
base rate 11% (2+ rounds)
- ▲ Recent equity round, but funding momentum is down (may be rescue financing)
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-01-15 | Other | €2.4M | BroadOak Capital Partners,Roslin Foundation | View deal → |
| 2022-04-08 | Other | €3.8M | Calculus Capital,Dr Jonathan Milner,Meltwind,Par Equity,Scottish Enterprise | View deal → |